Your browser doesn't support javascript.
loading
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Lee, Jung Won; Kim, Nayoung; Nam, Ryoung Hee; Lee, Sun Min; Soo In, Choi; Kim, Jung Mogg; Lee, Dong Ho.
  • Lee JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Kim N; Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
  • Nam RH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Lee SM; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine.
  • Soo In C; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Kim JM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Lee DH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
J Gastroenterol Hepatol ; 34(4): 666-672, 2019 Apr.
Article en En | MEDLINE | ID: mdl-30726563
ABSTRACT
BACKGROUND AND

AIM:

Failure of bismuth quadruple therapy for Helicobacter pylori eradication is frequently observed. To increase the eradication rate, comprehensive analyses need to be performed regarding risk factors of bismuth quadruple therapy failure based on complete standard culture and antimicrobial susceptibility testing results.

METHODS:

Patients with history of failed first therapy who had H. pylori colonies isolated from culture and successful minimum inhibitory concentration (MIC) test were enrolled. Esomeprazole, bismuth, metronidazole, and tetracycline (quadruple) therapies for 7 or 14 days were given. Eradication rate, treatment compliance, adverse events, and risk factors for the failure of bismuth quadruple therapy were analyzed.

RESULTS:

A total 54 patients were enrolled. Overall eradication rate in the present study was 88.8%. The eradication rate for cases with metronidazole resistance such as MIC 8-16 µg/mL or 16-32 µg/mL was 92.8% (13/14). For cases with high level metronidazole resistance (MIC > 32 µg/mL), the eradication rate was only 60% (6/10). Multivariate analysis regarding compliance, treatment duration, age > 60, three kinds of metronidazole MICs, tetracycline MIC > 4 µg/mL, adverse events and any other parameters, "metronidazole resistance, high level (MIC > 32 µg/mL)" was the only independent risk factor for eradication failure (P = 0.007).

CONCLUSION:

For cases with metronidazole resistance at MIC > 32 µg/mL, rescue therapy other than bismuth-containing quadruple therapy is needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bismuto / Helicobacter pylori / Infecciones por Helicobacter / Insuficiencia del Tratamiento / Gastritis / Antibacterianos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bismuto / Helicobacter pylori / Infecciones por Helicobacter / Insuficiencia del Tratamiento / Gastritis / Antibacterianos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article